LI
EIGR

Leap Investments’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Leap Investments’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-357
Closed -$159K – 603
2019
Q4 		$159K Buy
+357
New +$127K 0.07% 341
2019
Q3 		– Sell
-454
Closed -$144K – 514
2019
Q2 		$144K Buy
+454
New +$157K 0.19% 183

Other funds holding EIGR

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Leap Investments's EIGR Position: Q1 2020 in Review

Leap Investments sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2020, closing a stake of 357 shares — an estimated $159K sold.

Leap Investments first reported a position in EIGR in Q2 2019 and held it in 2 quarters. The position peaked at $159K in Q4 2019. 93 funds tracked by Wall St. Rank hold EIGR as of Q1 2020.

  • Leap Investments reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Leap Investments sold 357 Eiger BioPharmaceuticals, Inc. shares in Q1 2020, an estimated $159K.
  • Leap Investments first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2019 and held it in 2 quarters.
  • Leap Investments's Eiger BioPharmaceuticals, Inc. position peaked at $159K in Q4 2019.
  • 93 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.